Figure3: Distribution of TRACP 5b in our study groups. In patients without tumor 78.9 % are of normal activity, 21.1% are pathological elevated. Patients with tumor but without bone metastasis show normal activity in 68.3% and elevated levels of TRACP 5b in 31.7%. The TRACP 5b levels were normal in 35.3% of all patients with known bone metastasis and elevated in 64.7%.